Drug Profile

Oltipraz - Canopus BioPharma

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Wisconsin-Madison
Developer Canopus BioPharma
Class Chemoprotectants; Organic sulfur compounds; Pyrazines; Small molecules; Sulfhydryl compounds
Mechanism of Action DNA repair enzyme stimulants; Glutathione transferase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Cancer; Mucositis

Most Recent Events

23 Jun 2008 Canopus receives approval from the South African Medicines Control Council to begin a phase II trial with CB 1400 as a mucositis protective agent in patients with cancer
19 Jun 2008 Preclinical trials in Cancer in USA (PO)
19 Jun 2008 Preclinical pharmacodynamics data released by Canopus BioPharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com